Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Estrogen receptors localization and signaling pathways in DU-145 human prostate cancer cells

Full text
Author(s):
Souza, Deborah S. [1] ; Lombardi, Ana Paola G. [1] ; Vicente, Carolina M. [1] ; Lucas, Thais Fabiana G. [1] ; Erustes, Adolfo G. [1] ; Pereira, Gustavo J. S. [1] ; Porto, Catarina S. [1]
Total Authors: 7
Affiliation:
[1] Univ Fed Sao Paulo, Dept Pharmacol, Lab Expt Endocrinol, Escola Paulista Med, Rua Pedro de Toledo 669, Vila Clementino, BR-04039032 Sao Paulo, SP - Brazil
Total Affiliations: 1
Document type: Journal article
Source: Molecular and Cellular Endocrinology; v. 483, p. 11-23, MAR 1 2019.
Web of Science Citations: 1
Abstract

The aim of the present study was to investigate the subcellular localization of estrogen receptors ER alpha and ER beta in androgen-independent prostate cancer cell line DU-145, and the possible role of exportin CRM1 on ERs distribution. In addition, we evaluated the ERs contribution to activation of ERK1/2 and AKT. Immunostaining of ER alpha and ER beta was predominantly found in the extranuclear regions of DU-145 cells. CRM1 inhibitor Leptomycin B reduced drastically the presence of ER alpha and ER beta in the extranuclear regions and increased in the nuclei, indicating the possible involvement of CRM1 on ERs nuclear-cytoplasmic shuffling. 17 beta-estradiol (E2), ER alpha-selective agonist PPT and ER beta-selective agonist DPN induced a rapid increase on ERK1/2 phosphorylation. E2-induced ERK1/2 activation was partially inhibited when cells were pretreated with ER alpha- or ER beta-selective antagonists, and blocked by simultaneous pretreatment with both antagonists, suggesting ER alpha/beta heterodimers formation. Furthermore, E2 treatment did not activate AKT pathway. Therefore, we highlighted a possible crosstalk between extranuclear and nuclear ERs and their upstream and downstream signaling molecules as an important mechanism to control ER function as a potential therapeutic target in prostate cancer cells. (AU)

FAPESP's process: 14/05292-2 - Estrogen receptors and intracellular signaling pathways involved in the regulation of cell proliferation of testicular cancer and castration-resistant prostate cancer
Grantee:Catarina Segreti Porto
Support type: Regular Research Grants
FAPESP's process: 17/16060-3 - Intracellular signaling and role of the estrogen receptors in androgen-independent prostate cancer and testicular cancer cells.
Grantee:Catarina Segreti Porto
Support type: Regular Research Grants